November 14, 2024 10:56 AM EST
News Briefing

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

ENDPOINTS

Plus, news about Al­lo­gene, Telix, Cull­gen, Pul­ma­trix, Gilead, In­no­coll, Durect and Sen­sei:

Zai Lab’s $200M of­fer­ing: The Shang­hai-based drug­mak­er is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times